Skip to main content
. 2018 Aug 31;9(68):32958–32971. doi: 10.18632/oncotarget.26010

Figure 6. The DNA damage inhibitor olaparib re-sensitizes MAP17- and pH2AX-positive rectal tumors to radiotherapy treatment.

Figure 6

(A) Western blot analysis and relative quantification of the protein levels of phospho-γ-H2AX in colon tumor cell lines. (B) RT-qPCR showing the RNA levels of MAP17 in HCT116 and SW480 colon tumor cell lines. Samples were normalized to GAPDH. (C and D) Percentage of survival fraction after olaparid treatment (10 μM), radiology treatment (2 and 4 Gy) or their combination in HCT116 and SW480 colon tumor cell lines. (E and F) Determination of the IC50 value (concentration of the drug necessary to induce 50% cell death) for SW480 and HCT116 and colon tumor cells lines following treatment with olaparid and/or 5FU.